Agriculture Stocks, Cloud Computing Stocks and Social Networking Stocks
added to Directories for Investors at Investorideas.com
Sectors Include energy stocks mining, biotech stocks, renewable energy,
water
POINT ROBERTS, Wash., March 18, 2011 - www.InvestorIdeas.com, a global
investor research portal, specializing in sector research, reports
additions to the Investor Ideas member content include the agriculture stocks
directory in addition to the tech stocks directory featuring cloud computing and
social media stocks.
Investorideas.com covers leading sectors for investors with research tools
including stock directories, news, articles and featured stocks within each sector.
Sectors covered include oil and gas, natural gas, defense, biotech, mining,
nanotech, water, tech, agriculture and other high profile sectors.
The agriculture stocks directory has been one of the most visited pages on the
site for several months as global food concerns and prices rise.
Preview the agriculture stocks directory: http://www.investorideas.com/MSS/
Arg_Stock_List.asp
Investor Ideas membership currently features eleven stock directories, including
one of the largest green and renewable energy stocks directory online, featuring
over 1200 green publicly traded companies .
Visit the Investor Ideas membership page to learn more at: http://
www.investorideas.com/membership/
Additional stock directories at Investorideas.com for investors:
Renewable Energy Stocks Directory - Global Green and Renewable Energy
Stocks Directory in PDF format includes over 1200 stocks on the TSX, TSX
Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global
Stock Exchanges . The directory features hyperlinks to stocks symbol(s),
company’s URL and company’s description. The directory includes info and links
on Alternative Energy Funds, Biogas and Ethanol Stocks, Energy Efficiency
Stocks, Flywheel Stocks, Fuel Cell Stocks, Geothermal Stocks, Hydrogen
Production, Micro Turbine Stocks, Solar Stocks, Smart Grid Stocks, Green
Transportation, Wind Power and Wind Energy Stocks and Green Infrastructure
Stocks. For investors following green stocks, this is the most comprehensive
global stock directory online.
Mining and Gold Stocks Directory - Global Mining and Gold Stocks Directory
in PDF format lists over 1100 publicly traded mining companies. Mining and
metals investors can research gold and mining stocks with the mining stocks
directory, featuring Gold Stocks, Silver Stocks, Uranium Stocks, Copper Stocks,
Zinc Stocks and Precious Metals TSX, TSX Venture, OTC, NASDAQ, AMEX,
NYSE, ASX, AIM and other leading Stock Exchanges. directory features
hyperlinks to stocks symbol(s), company’s URL and company’s description.
Oil and Gas Stocks Directory - Global Oil and Gas Stocks Directory of Publicly
traded oil and gas stocks listed on the TSX, TSX Venture, OTC, NASDAQ,
AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The
comprehensive directory gives investors a full range and choice of micro cap
to large cap stocks in the energy sector. The directory in PDF format, features
hyperlinks to over 600 stocks symbol(s), company's URL and company's
description.
Coal Stocks Directory - Global Directory of Publicly traded Coal stocks listed
on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM, China
and other leading global Stock Exchanges . The comprehensive directory gives
investors a full range and choice of micro cap to large cap stocks in the coal
sector, including clean coal and coking coal stocks. The directory in PDF format,
features hyperlinks to coal stocks symbol(s), company's URL and company's
description.
Defense Stocks Directory - Global Defense and Homeland Security Stocks
Directory features publicly traded defense stocks listed on the TSX, TSX
Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global
Stock Exchanges. The directory, in PDF format, includes Homeland Security
Stocks, Aerospace and Defense Stocks, Biodefense Stocks, Security Stocks,
Energy Security Stocks and Infrastructure Stocks with hyperlinks to stocks
symbol(s), company's URL and company's description. For defense stocks
followers, this is one of the most comprehensive global stock directories available
to investors.
Water Stocks Directory - Global Water Stocks Directory of publicly traded water
stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX,
AIM and other leading global Stock Exchanges. The stock directory features
water stocks ranging from desalination companies to bottled water stocks, to
infrastructure, water treatment and technology as well as other sub sectors. The
directory in PDF format, features hyperlinks to stocks symbol(s), company's URL
and company's description. For investors following water stocks this is one of the
most comprehensive directories in the sector available.
Environment Stocks Directory - Global Green Stocks Directory of Publicly
traded Environmental Stocks listed on the TSX, TSX Venture, OTC, NASDAQ,
AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The
directory in PDF format, features hyperlinks to stocks symbol(s), company's URL
and company's description.
Fuel Cell Stocks Directory - Global Directory of Publicly traded Fuel Cell
Stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX,
AIM and other leading global Stock Exchanges. The directory includes small
cap, micro cap as well as large cap NYSE listed stocks for review. For green
investors looking for opportunities in the fuel cell sector, the comprehensive
global directory in PDF format provides a great research tool with hyperlinks to
stocks symbol(s), company's URL and company's description.
Biotech Stocks Directory - Global Directory of Publicly Traded Biotech,Pharma
and Life Sciences Stocks ,on the TSX, TSX Venture, OTC, NASDAQ, AMEX,
NYSE, ASX, AIM and other leading global Stock Exchanges . The directory
covers all sub sectors of biotech including nanotech, biodefense and stem cell
stocks. The directory includes small cap, micro cap as well as large cap NYSE
listed stocks for investors The comprehensive global directory in PDF format
provides a great research tool for biotechnology investors with hyperlinks to
stocks symbol(s), company's URL and company's description.
Natural Gas Stocks Directory - Global Directory of Publicly traded Natural Gas
Stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX,
AIM and other leading global Stock Exchanges. The directory includes small cap,
micro cap as well as large cap NYSE listed stocks for review. Natural gas stocks
included range from LNG, Coal Bed Methane to exploration and producers in
the sector. The directory in PDF format, features hyperlinks to stocks symbol(s),
company's URL and company's description.
Nanotechnology Stocks Directory - Investorideas.com global stock directory
of publicly traded nanotech stocks on the TSX, TSX Venture, OTC, NASDAQ,
AMEX, NYSE, ASX, AIM, Hong Kong and China and other leading Stock
Exchanges. Directory includes nanotech- biotech companies, nanotech water
and renewable energy companies and more. Directory features company
description, stock symbol and hyperlink to recent quote and info, link to website
and more.
Visit the Investor Ideas membership page to learn more at: http://
www.investorideas.com/membership/
Sign up for the free investor news letter and get stock alerts in leading
sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
Investor Ideas is a global financial media online destination specialized in sector
investing content.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as
an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we
offer no guarantees as to the accuracy of information presented. All Information relating to featured
companies is sourced from public documents and/ or the company and is not the opinion of our web sites.
This site is currently compensated by featured companies, news submissions and online advertising.
www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue
partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source – Investorideas.com
Friday, March 18, 2011
Biotech Sector Snapshot HIV Drug Development; (OTCBB: AEMD), (NYSE: BMY), (Nasdaq: GILD), (NYSE: PFE)
Industry Warns of Drug Resistance Potential for HIV Drugs
Point Roberts, WA - March 18, 2011- Investorideas.com releases an industry snapshot on HIV- AIDS drug makers and recent data that suggests the HIV virus has developed drug resistance and that drug industry is not acting fast enough to get new drugs into the pipeline to combat the potential threats.
Company snapshots include Gilead Sciences, Inc. (NasdaqGS: GILD), the largest player in HIV/AIDS products and medical technology companyAethlon Medical (OTCBB: AEMD).
Aethlon Medical (OTCBB: AEMD) is betting that its medical technology,
Hemopurifier® may offer solutions. Human studies have documented the ability of the Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.
"In the absence of a cure for AIDS, the drug industry responded with antiviral regimens that have allowed HIV-infected individuals the ability to effectively manage their disease," stated Jim Joyce, CEO at Aethlon Medical. "However, with a shrinking drug pipeline, the big question now is who is going to help these individuals at the point they become resistant to drug regimens?"
"Much like dialysis has extended the lives of those with kidney failure, we have created a therapeutic filtration device known as the Hemopurifier® that provides a device mechanism to address all circulating HIV strains, including those resistant to HIV drug therapies. Additionally, the device fills the unmet medical need of clearing immunosuppressive toxins that are shed by the virus to deplete immune cells, which is the hallmark of AIDS," concluded Joyce.
In the absence of drug therapy, Aethlon recently demonstrated immune function improvement and a greater than 90% viral load reduction in an AIDS patient as the result of 12 treatments administered over the course of one month.
UNAIDS recently reported in a press release, "Millions of people in developing countries now depend on a steady supply of affordable first-line treatment for HIV. If their treatment is interrupted, which can lead to drug resistance, these patients will have to switch to a second-line regimen. That can be at least six times more expensive than the first-line regimen," said Dr Gottfried Hirnschall, Director of WHO's HIV/AIDS Department.
A recent article on Bloomberg.com entitled , HIV Drug Development Falters as Merck, Bristol-Myers Struggle With Success" reports "Without a steady stream of new medicines to attack the virus in different ways, drug resistance will develop, leaving more patients without a viable treatment, said Scott Hammer, a professor of medicine at Columbia University in New York.
"If we are complacent, resistance will start to spread against the key components of our therapies," Hammer said in an interview. "We need to be ready for that because we won't be able to catch up after it happens."
Link to full story: http://www.bloomberg.com/news/2011-03-14/gilead-s-high-bar-for-aids-drugs-means-new-development-withers.html
At the end of 2009, nearly 15 million people were estimated to be in need of antiretroviral treatment for HIV and 5.2 million people had access to the life-saving therapy. Source: UNAIDS
UNDP,WHO.
Biotech/Pharma Sector Snapshot
Products HIV/AIDS
Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) is the first and only once-daily single tablet regimen for the treatment of HIV infection in adults. It is intended for use as a stand-alone therapy, or in combination with other antiretrovirals, and combines Gilead's Truvada® (emtricitabine and tenofovir disoproxil fumarate) with Sustiva® (efavirenz), manufactured by Bristol-Myers Squibb. ( U.S. approval, 2006; E.U. approval, 2007.)
Emtriva® (emtricitabine) is a once-daily oral nucleoside reverse transcriptase inhibitor (NRTI) used in combination with other antiretroviral agents for the treatment of HIV infection in adults. Emtriva is also available as an oral solution for use in pediatric patients. ( U.S. and E.U. approval, 2003.)
Truvada® (emtricitabine and tenofovir disoproxil fumarate) is a fixed-dose once-daily combination pill containing Viread® and Emtriva®. It is used in combination with other antiretroviral agents for the treatment of HIV infection in adults. ( U.S. approval, 2004; E.U. approval, 2005.)
Viread® (tenofovir disoproxil fumarate) is a once-daily oral nucleotide reverse transcriptase inhibitor (NtRTI) for the treatment of HIV infection in adults and adolescents in combination with other antiretroviral agents. ( U.S. approval, 2001; E.U. approval, 2002.) Viread® was also approved in 2008 as a treatment for chronic hepatitis B in adults. ( U.S. and EU approval, 2008.)
Company Snapshot
About Aethlon Medical ( OTCBB:AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
1.Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2.Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3.Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4.Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings .
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Industry Warns of Drug Resistance Potential for HIV Drugs
Point Roberts, WA - March 18, 2011- Investorideas.com releases an industry snapshot on HIV- AIDS drug makers and recent data that suggests the HIV virus has developed drug resistance and that drug industry is not acting fast enough to get new drugs into the pipeline to combat the potential threats.
Company snapshots include Gilead Sciences, Inc. (NasdaqGS: GILD), the largest player in HIV/AIDS products and medical technology companyAethlon Medical (OTCBB: AEMD).
Aethlon Medical (OTCBB: AEMD) is betting that its medical technology,
Hemopurifier® may offer solutions. Human studies have documented the ability of the Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.
"In the absence of a cure for AIDS, the drug industry responded with antiviral regimens that have allowed HIV-infected individuals the ability to effectively manage their disease," stated Jim Joyce, CEO at Aethlon Medical. "However, with a shrinking drug pipeline, the big question now is who is going to help these individuals at the point they become resistant to drug regimens?"
"Much like dialysis has extended the lives of those with kidney failure, we have created a therapeutic filtration device known as the Hemopurifier® that provides a device mechanism to address all circulating HIV strains, including those resistant to HIV drug therapies. Additionally, the device fills the unmet medical need of clearing immunosuppressive toxins that are shed by the virus to deplete immune cells, which is the hallmark of AIDS," concluded Joyce.
In the absence of drug therapy, Aethlon recently demonstrated immune function improvement and a greater than 90% viral load reduction in an AIDS patient as the result of 12 treatments administered over the course of one month.
UNAIDS recently reported in a press release, "Millions of people in developing countries now depend on a steady supply of affordable first-line treatment for HIV. If their treatment is interrupted, which can lead to drug resistance, these patients will have to switch to a second-line regimen. That can be at least six times more expensive than the first-line regimen," said Dr Gottfried Hirnschall, Director of WHO's HIV/AIDS Department.
A recent article on Bloomberg.com entitled , HIV Drug Development Falters as Merck, Bristol-Myers Struggle With Success" reports "Without a steady stream of new medicines to attack the virus in different ways, drug resistance will develop, leaving more patients without a viable treatment, said Scott Hammer, a professor of medicine at Columbia University in New York.
"If we are complacent, resistance will start to spread against the key components of our therapies," Hammer said in an interview. "We need to be ready for that because we won't be able to catch up after it happens."
Link to full story: http://www.bloomberg.com/news/2011-03-14/gilead-s-high-bar-for-aids-drugs-means-new-development-withers.html
At the end of 2009, nearly 15 million people were estimated to be in need of antiretroviral treatment for HIV and 5.2 million people had access to the life-saving therapy. Source: UNAIDS
UNDP,WHO.
Biotech/Pharma Sector Snapshot
- Aethlon Medical (OTCBB: AEMD) trading at $0.14
- Bristol-Myers Squibb Company (NYSE: BMY) trading at $25.77 0.34 (1.34%) 10:58AM EDT
- Gilead Sciences, Inc. (NasdaqGS: GILD) trading at $40.64, up 0.33 (0.82%) 10:59AM EDT
- GlaxoSmithKline (NYSE: GSK) trading at $ 37.33, down 0.01 (0.03%) 11:06AM EDT
- Johnson & Johnson (NYSE: JNJ) trading at $58.5, up 0.43 (0.74%) 11:08AM EDT
- Pfizer, Inc. (NYSE: PFE) trading at $ 20.06, up 0.18 (0.88%) 11:09AM EDT
Products HIV/AIDS
Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) is the first and only once-daily single tablet regimen for the treatment of HIV infection in adults. It is intended for use as a stand-alone therapy, or in combination with other antiretrovirals, and combines Gilead's Truvada® (emtricitabine and tenofovir disoproxil fumarate) with Sustiva® (efavirenz), manufactured by Bristol-Myers Squibb. ( U.S. approval, 2006; E.U. approval, 2007.)
Emtriva® (emtricitabine) is a once-daily oral nucleoside reverse transcriptase inhibitor (NRTI) used in combination with other antiretroviral agents for the treatment of HIV infection in adults. Emtriva is also available as an oral solution for use in pediatric patients. ( U.S. and E.U. approval, 2003.)
Truvada® (emtricitabine and tenofovir disoproxil fumarate) is a fixed-dose once-daily combination pill containing Viread® and Emtriva®. It is used in combination with other antiretroviral agents for the treatment of HIV infection in adults. ( U.S. approval, 2004; E.U. approval, 2005.)
Viread® (tenofovir disoproxil fumarate) is a once-daily oral nucleotide reverse transcriptase inhibitor (NtRTI) for the treatment of HIV infection in adults and adolescents in combination with other antiretroviral agents. ( U.S. approval, 2001; E.U. approval, 2002.) Viread® was also approved in 2008 as a treatment for chronic hepatitis B in adults. ( U.S. and EU approval, 2008.)
Company Snapshot
About Aethlon Medical ( OTCBB:AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
1.Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2.Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3.Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4.Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings .
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Effective March 15, 2011
Thursday, March 17, 2011
Biotech/Pharma Sector Close-Up; (OTCBB: AEMD), (NYSE: BMY), (Nasdaq: GILD), (NYSE: PFE)
Point Roberts, WA - March 18, 2011 - Investorideas.com, a leader in investor sector research including biotech and pharma stocks releases a sector snapshot on the HIV- AIDS drug makers and recent data that suggests the HIV virus may be following the path of bacteria that has developed drug resistance and that drug industry is not acting fast enough to get new drugs into the pipeline to combat the potential threats.
In that light, small player Aethlon Medical (OTCBB: AEMD) is betting that its medical technology,
Hemopurifier® may offer solutions. Human studies have documented the ability of the Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.
"In the absence of a cure for AIDS, the drug industry responded with antiviral regimens that have allowed HIV-infected individuals the ability to effectively manage their disease," stated Jim Joyce, CEO at Aethlon Medical. "However, with a shrinking drug pipeline, the big question now is who is going to help these individuals at the point they become resistant to drug regimens?"
"Much like dialysis has extended the lives of those with kidney failure, we have created a therapeutic filtration device known as the Hemopurifier® that provides a device mechanism to address all circulating HIV strains, including those resistant to HIV drug therapies. Additionally, the device fills the unmet medical need of clearing immunosuppressive toxins that are shed by the virus to deplete immune cells, which is the hallmark of AIDS," concluded Joyce.
In the absence of drug therapy, Aethlon recently demonstrated immune function improvement and a greater than 90% viral load reduction in an AIDS patient as the result of 12 treatments administered over the course of one month.
UNAIDS recently reported in a press release, "Millions of people in developing countries now depend on a steady supply of affordable first-line treatment for HIV. If their treatment is interrupted, which can lead to drug resistance, these patients will have to switch to a second-line regimen. That can be at least six times more expensive than the first-line regimen," said Dr Gottfried Hirnschall, Director of WHO's HIV/AIDS Department.
A recent article on Bloomberg.com entitled, HIV Drug Development Falters as Merck, Bristol-Myers Struggle With Success" reports "Without a steady stream of new medicines to attack the virus in different ways, drug resistance will develop, leaving more patients without a viable treatment, said Scott Hammer, a professor of medicine at Columbia University in New York.
"If we are complacent, resistance will start to spread against the key components of our therapies," Hammer said in an interview. "We need to be ready for that because we won't be able to catch up after it happens."
Link to full story: http://www.bloomberg.com/news/2011-03-14/gilead-s-high-bar-for-aids-drugs-means-new-development-withers.html
At the end of 2009, nearly 15 million people were estimated to be in need of antiretroviral treatment for HIV and 5.2 million people had access to the life-saving therapy. Source: UNAIDS
UNDP,WHO.
Biotech/Pharma Sector Snapshot
About Aethlon Medical ( OTCBB:AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
1.Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2.Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3.Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4.Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings .
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Point Roberts, WA - March 18, 2011 - Investorideas.com, a leader in investor sector research including biotech and pharma stocks releases a sector snapshot on the HIV- AIDS drug makers and recent data that suggests the HIV virus may be following the path of bacteria that has developed drug resistance and that drug industry is not acting fast enough to get new drugs into the pipeline to combat the potential threats.
In that light, small player Aethlon Medical (OTCBB: AEMD) is betting that its medical technology,
Hemopurifier® may offer solutions. Human studies have documented the ability of the Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.
"In the absence of a cure for AIDS, the drug industry responded with antiviral regimens that have allowed HIV-infected individuals the ability to effectively manage their disease," stated Jim Joyce, CEO at Aethlon Medical. "However, with a shrinking drug pipeline, the big question now is who is going to help these individuals at the point they become resistant to drug regimens?"
"Much like dialysis has extended the lives of those with kidney failure, we have created a therapeutic filtration device known as the Hemopurifier® that provides a device mechanism to address all circulating HIV strains, including those resistant to HIV drug therapies. Additionally, the device fills the unmet medical need of clearing immunosuppressive toxins that are shed by the virus to deplete immune cells, which is the hallmark of AIDS," concluded Joyce.
In the absence of drug therapy, Aethlon recently demonstrated immune function improvement and a greater than 90% viral load reduction in an AIDS patient as the result of 12 treatments administered over the course of one month.
UNAIDS recently reported in a press release, "Millions of people in developing countries now depend on a steady supply of affordable first-line treatment for HIV. If their treatment is interrupted, which can lead to drug resistance, these patients will have to switch to a second-line regimen. That can be at least six times more expensive than the first-line regimen," said Dr Gottfried Hirnschall, Director of WHO's HIV/AIDS Department.
A recent article on Bloomberg.com entitled, HIV Drug Development Falters as Merck, Bristol-Myers Struggle With Success" reports "Without a steady stream of new medicines to attack the virus in different ways, drug resistance will develop, leaving more patients without a viable treatment, said Scott Hammer, a professor of medicine at Columbia University in New York.
"If we are complacent, resistance will start to spread against the key components of our therapies," Hammer said in an interview. "We need to be ready for that because we won't be able to catch up after it happens."
Link to full story: http://www.bloomberg.com/news/2011-03-14/gilead-s-high-bar-for-aids-drugs-means-new-development-withers.html
At the end of 2009, nearly 15 million people were estimated to be in need of antiretroviral treatment for HIV and 5.2 million people had access to the life-saving therapy. Source: UNAIDS
UNDP,WHO.
Biotech/Pharma Sector Snapshot
- Aethlon Medical (OTCBB: AEMD) trading at $0.15, up 0.01 (5.71%)
- Bristol-Myers Squibb Company (NYSE: BMY ) trading at $25.37, up 0.40 (1.60%) 1:02PM EDT
- Gilead Sciences, Inc. (NasdaqGS: GILD ) trading at $40.17, up 0.33 (0.83%) 1:03PM EDT
- GlaxoSmithKline (NYSE: GSK ) trading at $40.18, up 0.34 (0.85%) 1:04PM EDT
- Johnson & Johnson (NYSE: JNJ ) trading at $58.17, up 0.51 (0.88%) 1:05PM EDT
- Pfizer, Inc.(NYSE: PFE ) trading at $19.70, up 0.40 (2.07%) 1:05PM EDT
- Dow 11,755.82 +142.52 +1.23%
- Nasdaq 2,651.69 +34.87 +1.33%
- S&P 500 1,274.35 +17.47 +1.39%
- 10 Yr Bond(%) 3.2740% +0.0620
- Oil 100.84 +2.86 +2.92%
- Gold 1,396.00 0.00 0.00%
About Aethlon Medical ( OTCBB:AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
1.Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2.Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3.Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4.Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings .
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Electric Car Stocks Snapshot; (NasdaqGM: AONE), (NASDAQ: HEV), (OTCBB: EVCA)), (NYSE: NRG), (NASDAQ: TSLA)
Point Roberts, WA - March 18, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com a leader in cleantech investor research, reports on electric car stocks and battery stocks trading for March 18th. A recent report by IDTechEx calls the hybrid and EV cars the new gold rush 2011- 2021.
With higher oil prices, the sector has had some ups and downs, with the overall market volatility. Long term- the green car enthusiasts are bullish. Just like the cars, most of the stocks in the sector are trading up and in the green this morning.
"Hybrid and Pure Electric Cars 2011-2021" and "Car Traction Batteries - The New Gold Rush 2011-2021"
Good volume growth but greater value growth The 30.6 million EVs sold in 2011 will rise to 51.3 million in 2021 but the value of the market will grow by far more because larger and more expensive vehicles are now rapidly adopting the technology. Motorcycles, military vehicles, buses and earthmovers are among them. Hybrids will rise from about 50% to about 60% of the value market through the decade. In ten years from now, a far higher percentage of the global output of light industrial vehicles, commercial vehicles and cars will be EVs. The new report gives the detail, forecasting numbers, unit value and total market value for each applicational sector with many original tables giving subsets of the data and a large number of profiles of current and planned activities of the participants. Some EV sectors were hit by the global financial meltdown but are recovering. Many sectors now benefit from the tsunami wave of government benefits, technical innovations and new models becoming available. We evaluate these aspects and the market drivers, including what users really need. Battery, motor and other technology is explained and forecasted as well. This report "Electric Vehicles 2011-2021" is a sister report to IDTechEx reports about the two most important subsectors of the EV business - "Hybrid and Pure Electric Cars 2011-2021" and "Car Traction Batteries - The New Gold Rush 2011-2021".
For more information visit http://www.researchandmarkets.com/research/a7c011/electric_vehicles
EV Sector Snapshot Morning Trading March 18th
EVCARCO (OTC.BB: EVCA) to Showcase Latest Alternative Energy Units at Ft. Worth Auto Show
CNG Units to Be Displayed for Commercial Customers
Full news;http://www.investorideas.com/CO/EVCA/news/2011/03171.asp
Company Snapshots
EVCARCO (OTC.BB: EVCA) - Green, Electric Cars and Natural Gas Vehicles
EVCARCO (OTC.BB:EVCA) (www.evcarco.com) is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
NRG Energy, Inc., a Fortune 500 and S&P 500 Index company, owns and operates one of the country's largest and most diverse power generation portfolios. Headquartered in Princeton, NJ, the Company's power plants provide nearly 26,000 megawatts of generation capacity—enough to supply more than 20 million homes. NRG's retail businesses, Reliant Energy and Green Mountain Energy Company, combined serve more than 1.8 million residential, business, commercial and industrial customers. With investments in solar, wind and nuclear power, as well as electric vehicle infrastructure, NRG is working to help America's transition to a clean energy economy.
NRG Energy is a founding member of the Electrification Coalition, a nonpartisan, not-for-profit group of business leaders committed to promoting policies and actions that facilitate the deployment of electric vehicles on a mass scale. More information is available at www.nrgenergy.com.
About eVgo
eVgo is the nation's first privately funded, comprehensive electric vehicle ecosystem. The eVgo network gives EV owners new freedom and range confidence via home charging and fast-charging stations conveniently located at major retailers, employers and along highways across eVgo cities. eVgo allows EV owners to avoid paying large up-front costs for a home charger and provides unlimited use remote charging—all for one low monthly fee. To find out more, or to join the eVgo network, visit www.evgonetwork.com.
More News:
Find electric vehicle charging stations on Google Maps
Wednesday, March 9, 2011 at 9:30 AM
[Cross-posted from the Google.org Blog]
http://google-latlong.blogspot.com/2011/03/find-electric-vehicle-charging-stations.html
Research electric car stocks and green auto stocks , lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 10 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
Investors - sign up for free stock alerts and investor news alerts
http://www.investorideas.com/Resources/Newsletter.asp
About Our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas is compensated by featured green companies EVCARCO (OTCBB: EVCA) is a showcase stock at Investorideas.com and compensated the site 500,000 144 shares in lieu of cash compensation.
For more information contact:
Email: dvanzant@investorideas.com or Cali at cvanzant@investorideas.com
Source: www.Investorideas.com
Point Roberts, WA - March 18, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com a leader in cleantech investor research, reports on electric car stocks and battery stocks trading for March 18th. A recent report by IDTechEx calls the hybrid and EV cars the new gold rush 2011- 2021.
With higher oil prices, the sector has had some ups and downs, with the overall market volatility. Long term- the green car enthusiasts are bullish. Just like the cars, most of the stocks in the sector are trading up and in the green this morning.
"Hybrid and Pure Electric Cars 2011-2021" and "Car Traction Batteries - The New Gold Rush 2011-2021"
Good volume growth but greater value growth The 30.6 million EVs sold in 2011 will rise to 51.3 million in 2021 but the value of the market will grow by far more because larger and more expensive vehicles are now rapidly adopting the technology. Motorcycles, military vehicles, buses and earthmovers are among them. Hybrids will rise from about 50% to about 60% of the value market through the decade. In ten years from now, a far higher percentage of the global output of light industrial vehicles, commercial vehicles and cars will be EVs. The new report gives the detail, forecasting numbers, unit value and total market value for each applicational sector with many original tables giving subsets of the data and a large number of profiles of current and planned activities of the participants. Some EV sectors were hit by the global financial meltdown but are recovering. Many sectors now benefit from the tsunami wave of government benefits, technical innovations and new models becoming available. We evaluate these aspects and the market drivers, including what users really need. Battery, motor and other technology is explained and forecasted as well. This report "Electric Vehicles 2011-2021" is a sister report to IDTechEx reports about the two most important subsectors of the EV business - "Hybrid and Pure Electric Cars 2011-2021" and "Car Traction Batteries - The New Gold Rush 2011-2021".
For more information visit http://www.researchandmarkets.com/research/a7c011/electric_vehicles
EV Sector Snapshot Morning Trading March 18th
- A123 Systems, Inc. (NasdaqGM: AONE) trading at $7.75, up 0.06 (0.78%) 10:44AM EDT
- ENER1, Inc. (NASDAQ: HEV) trading at $ $3.02, down 0.03 (0.98%) 10:45AM EDT
- Ecotality, Inc. (NasdaqCM: ECTY) trading at $3.3680, up 0.0080 (0.24%)
- EVCARCO (OTCBB: EVCA)) trading at $ 0.03
- NRG Energy, Inc.(NYSE: NRG ) at $20.45, up 0.25 (1.21%)
- Tesla Motors, Inc. (NASDAQ: TSLA) trading at $22.98, up 0.16 (0.70%) 10:47AM EDT
- UQM Technologies, Inc. (NYSE Amex: UQM) trading at $2.81, up 0.12 (4.46%) 10:30AM EDT
- ZENN MOTOR COMPANY INC. (CDNX: ZNN.V) trading at$1.92, up 0.05 (2.67%)
- Dow 11,778.90 +165.60 +1.43%
- Nasdaq 2,656.42 +39.60 +1.51%
- S&P 500 1,277.30 +20.42 +1.62%
- 10 Yr Bond(%) 3.2790% +0.0670
- Oil 100.27 +2.29 +2.34%
- Gold 1,396.00 0.00 0.00%
EVCARCO (OTC.BB: EVCA) to Showcase Latest Alternative Energy Units at Ft. Worth Auto Show
CNG Units to Be Displayed for Commercial Customers
Full news;http://www.investorideas.com/CO/EVCA/news/2011/03171.asp
Company Snapshots
EVCARCO (OTC.BB: EVCA) - Green, Electric Cars and Natural Gas Vehicles
EVCARCO (OTC.BB:EVCA) (www.evcarco.com) is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
NRG Energy, Inc., a Fortune 500 and S&P 500 Index company, owns and operates one of the country's largest and most diverse power generation portfolios. Headquartered in Princeton, NJ, the Company's power plants provide nearly 26,000 megawatts of generation capacity—enough to supply more than 20 million homes. NRG's retail businesses, Reliant Energy and Green Mountain Energy Company, combined serve more than 1.8 million residential, business, commercial and industrial customers. With investments in solar, wind and nuclear power, as well as electric vehicle infrastructure, NRG is working to help America's transition to a clean energy economy.
NRG Energy is a founding member of the Electrification Coalition, a nonpartisan, not-for-profit group of business leaders committed to promoting policies and actions that facilitate the deployment of electric vehicles on a mass scale. More information is available at www.nrgenergy.com.
About eVgo
eVgo is the nation's first privately funded, comprehensive electric vehicle ecosystem. The eVgo network gives EV owners new freedom and range confidence via home charging and fast-charging stations conveniently located at major retailers, employers and along highways across eVgo cities. eVgo allows EV owners to avoid paying large up-front costs for a home charger and provides unlimited use remote charging—all for one low monthly fee. To find out more, or to join the eVgo network, visit www.evgonetwork.com.
More News:
Find electric vehicle charging stations on Google Maps
Wednesday, March 9, 2011 at 9:30 AM
[Cross-posted from the Google.org Blog]
http://google-latlong.blogspot.com/2011/03/find-electric-vehicle-charging-stations.html
Research electric car stocks and green auto stocks , lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 10 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
Investors - sign up for free stock alerts and investor news alerts
http://www.investorideas.com/Resources/Newsletter.asp
About Our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas is compensated by featured green companies EVCARCO (OTCBB: EVCA) is a showcase stock at Investorideas.com and compensated the site 500,000 144 shares in lieu of cash compensation.
For more information contact:
Email: dvanzant@investorideas.com or Cali at cvanzant@investorideas.com
Source: www.Investorideas.com
Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Financial Results for 2010 and Clinical Development and Business Highlights
LINCOLNSHIRE, Ill. - March 17, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced financial results for the year ended December 31, 2010 and clinical development and business highlights.
Financial Results for 2010
As of December 31, 2010, BioSante's cash balance was approximately $38.2 million as compared to $29.9 million at December 31, 2009. Subsequently, on March 9, 2011, the company completed a registered direct offering, resulting in net proceeds of approximately $23.8 million. Consequently, on March 10, 2011, BioSante's cash balance was approximately $54 million. "We are very pleased with our progress over the last year as well as our current cash balance," said Stephen M. Simes, BioSante's president and CEO. "Through careful cash management and our financing strategy, we believe we now have removed any near-term financial risk from BioSante, and our current cash balance is sufficient to finance our operations and LibiGel clinical development well into 2012, without need for additional funds."
BioSante's net loss was $46.2 million or $0.70 per share for the year ended December 31, 2010, compared to a net loss of $47.5 million or $1.40 per share for 2009. This decrease in net loss was due primarily to transaction and non-cash technology related expenses in 2009, associated with the company's merger with Cell Genesys, Inc., offset by increased LibiGel® clinical development expenses in 2010.
LibiGel® Clinical Highlights
The increased LibiGel clinical development expenses during 2010 was the result of steady progress in BioSante's LibiGel Phase III clinical program. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product. In February 2011, the company announced completion of enrollment in the first of two LibiGel Phase III efficacy trials, and expects enrollment in the second efficacy trial to be completed in the near future. BioSante continues to expect data from the two efficacy trials in Fall 2011.
BioSante also is conducting a Phase III safety study of LibiGel which has enrolled almost 3,000 women resulting in 3,200 women-years of safety data. A maximum of 4,000 patients will be enrolled in the study and be followed for a total of five years. However, BioSante can use the safety study data as part of a New Drug Application (NDA) submission after an average of 12 months of exposure to LibiGel or placebo. The study's independent data monitoring committee (DMC) has met five times and voted unanimously each time that the study should continue as per FDA-agreed protocol, without modification.
Pipeline Updates
In addition to the LibiGel clinical program, BioSante has a number of pipeline candidates in development, including a broad portfolio of cancer vaccines. Clinical trials of BioSante's Cancer Vaccines are being conducted to treat leukemia, pancreatic cancer and breast cancer, among other cancer types. These studies are being conducted in cooperation with The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, and are sponsored or funded at little or no cost to BioSante. Through March 2011, four of these cancer vaccines, the Pancreas Cancer Vaccine, Chronic Myeloid Leukemia Cancer Vaccine, Melanoma Cancer Vaccine, and Acute Myeloid Leukemia Cancer Vaccine, have received FDA Orphan Drug designations.
BioSante's pipeline also includes Bio-T-Gel™, a testosterone gel for male hypogonadism, which is licensed to Teva Pharmaceuticals for development and marketing. BioSante also has a licensing agreement with Pantarhei Bioscience for the development of the Pill-Plus triple component oral contraceptive which uses patented technology from BioSante. Pantarhei is engaged in several Phase II/III clinical studies with this product.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).
LINCOLNSHIRE, Ill. - March 17, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced financial results for the year ended December 31, 2010 and clinical development and business highlights.
Financial Results for 2010
As of December 31, 2010, BioSante's cash balance was approximately $38.2 million as compared to $29.9 million at December 31, 2009. Subsequently, on March 9, 2011, the company completed a registered direct offering, resulting in net proceeds of approximately $23.8 million. Consequently, on March 10, 2011, BioSante's cash balance was approximately $54 million. "We are very pleased with our progress over the last year as well as our current cash balance," said Stephen M. Simes, BioSante's president and CEO. "Through careful cash management and our financing strategy, we believe we now have removed any near-term financial risk from BioSante, and our current cash balance is sufficient to finance our operations and LibiGel clinical development well into 2012, without need for additional funds."
BioSante's net loss was $46.2 million or $0.70 per share for the year ended December 31, 2010, compared to a net loss of $47.5 million or $1.40 per share for 2009. This decrease in net loss was due primarily to transaction and non-cash technology related expenses in 2009, associated with the company's merger with Cell Genesys, Inc., offset by increased LibiGel® clinical development expenses in 2010.
LibiGel® Clinical Highlights
The increased LibiGel clinical development expenses during 2010 was the result of steady progress in BioSante's LibiGel Phase III clinical program. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product. In February 2011, the company announced completion of enrollment in the first of two LibiGel Phase III efficacy trials, and expects enrollment in the second efficacy trial to be completed in the near future. BioSante continues to expect data from the two efficacy trials in Fall 2011.
BioSante also is conducting a Phase III safety study of LibiGel which has enrolled almost 3,000 women resulting in 3,200 women-years of safety data. A maximum of 4,000 patients will be enrolled in the study and be followed for a total of five years. However, BioSante can use the safety study data as part of a New Drug Application (NDA) submission after an average of 12 months of exposure to LibiGel or placebo. The study's independent data monitoring committee (DMC) has met five times and voted unanimously each time that the study should continue as per FDA-agreed protocol, without modification.
Pipeline Updates
In addition to the LibiGel clinical program, BioSante has a number of pipeline candidates in development, including a broad portfolio of cancer vaccines. Clinical trials of BioSante's Cancer Vaccines are being conducted to treat leukemia, pancreatic cancer and breast cancer, among other cancer types. These studies are being conducted in cooperation with The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, and are sponsored or funded at little or no cost to BioSante. Through March 2011, four of these cancer vaccines, the Pancreas Cancer Vaccine, Chronic Myeloid Leukemia Cancer Vaccine, Melanoma Cancer Vaccine, and Acute Myeloid Leukemia Cancer Vaccine, have received FDA Orphan Drug designations.
BioSante's pipeline also includes Bio-T-Gel™, a testosterone gel for male hypogonadism, which is licensed to Teva Pharmaceuticals for development and marketing. BioSante also has a licensing agreement with Pantarhei Bioscience for the development of the Pill-Plus triple component oral contraceptive which uses patented technology from BioSante. Pantarhei is engaged in several Phase II/III clinical studies with this product.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).
Biotech Stock News Alert; Aethlon Medical, Inc. (OTCBB:AEMD) Updates Shareholders
San Diego, CA, March 17, 2011 � Investorideas.com newswire; Biotech and biodefense stock news; Aethlon Medical Shareholder Letter Aethlon Medical, Inc., (OTCBB:AEMD) disclosed that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.
Website: aethlonmedical.com
To our Shareholders:
As we advance our Hepatitis-C (HCV) treatment studies in India, we have also been active in our efforts to benefit from new government policies aimed at protecting U.S. civilian and military populations from bioterror and pandemic threats. This policy shift redefines the primary strategic objective of related government agencies to be the identification and support of innovative broad-spectrum countermeasures, technologies, and platforms. This is a considerable shift from the government�s previous focus of attempting to align a single drug or vaccine countermeasure with each pathogen threat. We remain convinced that our Hemopurifier� is the most advanced broad-spectrum countermeasure, technology, or platform.
Earlier this year, we were honored to be invited by The Department of Health and Humans Services (HHS) to present our Hemopurifier� as a broad-spectrum platform technology to multi-agency health officials on January 12th at the Washington Convention Center. Since this presentation, our bioterror and pandemic threat initiative has led to follow-on meetings and presentations, including a formal presentation to the Biomedical Advanced Research and Development Authority (BARDA) on February 15th. While the pursuit of government grants and contracts is not our primary focus, it is difficult to ignore a growing pipeline of new and evolving opportunities to advance our science with non-dilutive capital resources.
On February 8th, we were pleased to learn that the Defense Advanced Research Projects Agency (DARPA) released a broad agency announcement (BAA) entitled: �Dialysis Like Therapeutics� (DLT). The goal of the DLT program is to develop a portable device that removes �dirty� blood from the body, separates harmful agents, and returns �clean� blood to the body in a manner similar to dialysis treatment of kidney failure. While the device could have an impact across multiple areas of medicine, the target application for this device is sepsis. The envisioned device will be capable of removing at least 90% of unknown pathogens, toxins, and activated cells from a patient in one day. As stated in the BAA, targets for removal include viral pathogens referenced to include Hepatitis-C Virus (HCV), Human Immunodeficiency Virus (HIV), Influenza Bio-agents, Smallpox, and viral hemorrhagic fevers. As we have proven capabilities within the scope of this BAA, we plan to respond with a full proposal by April 1st.
If you are not familiar with DARPA, their mission is to maintain the technological superiority of the U.S. military and prevent technological surprise from harming our national security by sponsoring revolutionary, high-payoff research bridging the gap between fundamental discoveries and their military use. Innovation sponsored by DARPA has resulted in groundbreaking discoveries and life changing advances such as the internet. DARPA envisions that the device developed under this BAA would save the lives of thousands of military patients each year.
If selected to participate in the DLT program, we would anticipate a multifaceted role that would involve teaming with other industry partners to advance our core Hemopurifier� as an innovative dialysis-like multi-use platform technology able to selectively target deleterious pathogens and toxins from the entire circulatory system. We would also seek expand the capabilities of our technology platform as the basis for a device targeting to reduce the presence of circulating factors that are precursors to sepsis. Our goal would be to reduce the occurrence of sepsis as post-sepsis treatment strategies to inhibit the inflammation process including the modulation of inflammatory cytokines have yet to be proven clinically beneficial. It is also possible that we could participate in the advancement of portable blood pump technology required under the BAA that would be deployed to treat wounded warfighters with extracorporeal device technologies including current and future iterations of our Hemopurifier� technology. Regardless of outcome, it is truly gratifying to witness therapeutic filtration being the focal point of a government contract opportunity. This is especially true when it comes from an agency as scientifically adept as DARPA. Once we complete our submission to DARPA, I will be back in touch with an update on other activities.
On behalf of our dedicated team at Aethlon Medical, I thank you for your continued support.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier� to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company�s ability to raise capital when needed, including obtaining government grants, the Company�s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the ability to achieve commercialization in India as a result of the proposed treatment program at Medanta, The Medicity Institute, whether successful or not, the ability of the Hemopurifier� to improve the efficacy of SOC therapy against HCV, the Company�s ability to manufacture its products either internally or through outside companies and to create future generations of the Hemopurifier�, the impact of government regulations, patent protection on the Company�s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company�s Securities and Exchange Commission filings.
Disclaimer /Disclosure
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Visit the profile at Investorideas.com: http://www.investorideas.com/co/aemd/
San Diego, CA, March 17, 2011 � Investorideas.com newswire; Biotech and biodefense stock news; Aethlon Medical Shareholder Letter Aethlon Medical, Inc., (OTCBB:AEMD) disclosed that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.
Website: aethlonmedical.com
To our Shareholders:
As we advance our Hepatitis-C (HCV) treatment studies in India, we have also been active in our efforts to benefit from new government policies aimed at protecting U.S. civilian and military populations from bioterror and pandemic threats. This policy shift redefines the primary strategic objective of related government agencies to be the identification and support of innovative broad-spectrum countermeasures, technologies, and platforms. This is a considerable shift from the government�s previous focus of attempting to align a single drug or vaccine countermeasure with each pathogen threat. We remain convinced that our Hemopurifier� is the most advanced broad-spectrum countermeasure, technology, or platform.
Earlier this year, we were honored to be invited by The Department of Health and Humans Services (HHS) to present our Hemopurifier� as a broad-spectrum platform technology to multi-agency health officials on January 12th at the Washington Convention Center. Since this presentation, our bioterror and pandemic threat initiative has led to follow-on meetings and presentations, including a formal presentation to the Biomedical Advanced Research and Development Authority (BARDA) on February 15th. While the pursuit of government grants and contracts is not our primary focus, it is difficult to ignore a growing pipeline of new and evolving opportunities to advance our science with non-dilutive capital resources.
On February 8th, we were pleased to learn that the Defense Advanced Research Projects Agency (DARPA) released a broad agency announcement (BAA) entitled: �Dialysis Like Therapeutics� (DLT). The goal of the DLT program is to develop a portable device that removes �dirty� blood from the body, separates harmful agents, and returns �clean� blood to the body in a manner similar to dialysis treatment of kidney failure. While the device could have an impact across multiple areas of medicine, the target application for this device is sepsis. The envisioned device will be capable of removing at least 90% of unknown pathogens, toxins, and activated cells from a patient in one day. As stated in the BAA, targets for removal include viral pathogens referenced to include Hepatitis-C Virus (HCV), Human Immunodeficiency Virus (HIV), Influenza Bio-agents, Smallpox, and viral hemorrhagic fevers. As we have proven capabilities within the scope of this BAA, we plan to respond with a full proposal by April 1st.
If you are not familiar with DARPA, their mission is to maintain the technological superiority of the U.S. military and prevent technological surprise from harming our national security by sponsoring revolutionary, high-payoff research bridging the gap between fundamental discoveries and their military use. Innovation sponsored by DARPA has resulted in groundbreaking discoveries and life changing advances such as the internet. DARPA envisions that the device developed under this BAA would save the lives of thousands of military patients each year.
If selected to participate in the DLT program, we would anticipate a multifaceted role that would involve teaming with other industry partners to advance our core Hemopurifier� as an innovative dialysis-like multi-use platform technology able to selectively target deleterious pathogens and toxins from the entire circulatory system. We would also seek expand the capabilities of our technology platform as the basis for a device targeting to reduce the presence of circulating factors that are precursors to sepsis. Our goal would be to reduce the occurrence of sepsis as post-sepsis treatment strategies to inhibit the inflammation process including the modulation of inflammatory cytokines have yet to be proven clinically beneficial. It is also possible that we could participate in the advancement of portable blood pump technology required under the BAA that would be deployed to treat wounded warfighters with extracorporeal device technologies including current and future iterations of our Hemopurifier� technology. Regardless of outcome, it is truly gratifying to witness therapeutic filtration being the focal point of a government contract opportunity. This is especially true when it comes from an agency as scientifically adept as DARPA. Once we complete our submission to DARPA, I will be back in touch with an update on other activities.
On behalf of our dedicated team at Aethlon Medical, I thank you for your continued support.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier� to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company�s ability to raise capital when needed, including obtaining government grants, the Company�s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the ability to achieve commercialization in India as a result of the proposed treatment program at Medanta, The Medicity Institute, whether successful or not, the ability of the Hemopurifier� to improve the efficacy of SOC therapy against HCV, the Company�s ability to manufacture its products either internally or through outside companies and to create future generations of the Hemopurifier�, the impact of government regulations, patent protection on the Company�s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company�s Securities and Exchange Commission filings.
Disclaimer /Disclosure
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Visit the profile at Investorideas.com: http://www.investorideas.com/co/aemd/
Electric Car Stock News; EVCARCO (OTC.BB: EVCA) to Showcase Latest Alternative Energy Units at Ft. Worth Auto Show
FT. WORTH, TX - March 17, 2011 (Investorideas.com renewable energy/green newswire) - EVCARCO, Inc. (OTCBB:EVCA) announced that the Ft. Worth Auto Show at the Ft. Worth Convention Center opened today and runs through Sunday. EVCARCO is displaying its current green vehicle offerings in the Green Exhibitor Section, which is dedicated to eco-friendly products.
Mack Sanders, CEO of EVCARCO, stated, "With current government regulations and the need for compliance in the area of commercial units, EVCARCO is especially proud to present CNG Units to both Government and commercial clients. The ability for a fleet to reduce emissions, reduce hard costs for fuel and the ability to present an environmentally friendly fleet is significant for our Company."
The Company will also be exhibiting its current line of electric vehicles, charging stations, and CNG Units at the Dallas Auto Show, April 7th-10th at the Dallas Convention Center."
For more information on EVCARCO, Inc., please view: www.evcarco.com
EVCARCO Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
This Press Release contains certain forward-looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Contact:
Investor Relations Contact:
Jack Eversull
The Eversull Group, Inc.
972-571-1624
214-469-2361 fax
FT. WORTH, TX - March 17, 2011 (Investorideas.com renewable energy/green newswire) - EVCARCO, Inc. (OTCBB:EVCA) announced that the Ft. Worth Auto Show at the Ft. Worth Convention Center opened today and runs through Sunday. EVCARCO is displaying its current green vehicle offerings in the Green Exhibitor Section, which is dedicated to eco-friendly products.
Mack Sanders, CEO of EVCARCO, stated, "With current government regulations and the need for compliance in the area of commercial units, EVCARCO is especially proud to present CNG Units to both Government and commercial clients. The ability for a fleet to reduce emissions, reduce hard costs for fuel and the ability to present an environmentally friendly fleet is significant for our Company."
The Company will also be exhibiting its current line of electric vehicles, charging stations, and CNG Units at the Dallas Auto Show, April 7th-10th at the Dallas Convention Center."
For more information on EVCARCO, Inc., please view: www.evcarco.com
EVCARCO Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
This Press Release contains certain forward-looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Contact:
Investor Relations Contact:
Jack Eversull
The Eversull Group, Inc.
972-571-1624
214-469-2361 fax
Visit the EVCA showcase profile at Investorideas.com
Request News and Info on EVCA
Disclosure, Disclaimer/ EVCA is a paid advertising client on Investorideas.com and our renewable energy portals (500,000 144 shares).
Request News and Info on EVCA
Disclosure, Disclaimer/ EVCA is a paid advertising client on Investorideas.com and our renewable energy portals (500,000 144 shares).
Wednesday, March 16, 2011
Wind Stocks; Up, Up and Away
Company Snapshots for Broadwind Energy, Inc. (NasdaqGS: BWEN ), Clean Wind Energy Tower,
Inc. (OTCBB: CWET)
Point Roberts, WA –March 17, 2011 - Investorideas.com, a leader in cleantech stock research, reports
on recent wind stocks news and developments for wind stocks following a third up day in trading for the
sector. Investors have been turning to renewable stocks this week following the nuclear disaster in Japan.
Astute investors have already been betting on wind. In his most recent shareholder letter, Warren Buffett
stated, “MidAmerican will have 2,909 megawatts of wind generation in operation by the end of 2011,
more than any other regulated electric utility in the country. The total amount that MidAmerican has
invested or committed to wind is a staggering $5.4 billion. We can make this sort of investment because
MidAmerican retains all of its earnings, unlike other utilities that generally pay out most of what they
earn.”
Wind Stocks Snapshot; Morning Trading
Broadwind Energy, Inc. (NasdaqGS: BWEN ) trading at $1.45, up 0.07 (5.07%) 11:02AM EDT
China Ming Yang Wind Power Group (NYSE: MY ) trading at $ 9.39, up 0.09 (0.97%) 11:06AM EDT
Clean Wind Energy Tower, Inc. (OTCBB: CWET) trading at $0.24
Juhl Wind Inc. (OTCBB: JUHL) trading at $1.20, up 0.05 (4.35%)
Plutonic Power Corporation (PCC.TO) trading at $2.55, up 0.06 (2.41%)
Western Wind Energy Corp. (TSX.V: WND) trading at$1.50, up 0.06 (4.17%)
Market Snapshot
Dow 11,743.33 -112.09 -0.95%
Nasdaq 2,649.00 -18.33 -0.69%
S&P 500 1,269.32 -12.55 -0.98%
10 Yr Bond(%) 3.2640% -0.0590
Oil 98.34 +1.16 +1.19%
Gold 1,392.60 0.00 0.00%
Recent Wind News:
Plutonic Power Corporation (TSX: PCC) and Magma Energy Corp. are merging to form Alterra
Power Corp, a renewable power producer
Full news: http://www.investorideas.com/news/2011/renewable-energy/03154.asp
Goldwind Selects Broadwind to Supply Towers for Shady Oaks Project
Experience, flexibility and location made Broadwind the choice for tower localization by China’s
leading wind energy company
Full news: http://finance.yahoo.com/news/Goldwind-Selects-Broadwind-to-bw-29192890.html?x=0&.v=1
Clean Wind Energy Tower, Inc. (OTCBB: CWET) Files Unique Hydraulic System Patent
Maximizing the Capture and Use of Available Wind Tunnel Energy
ANNAPOLIS, MD - March 7, 2011 (InvestorIdeas.com Newswire) - Clean Wind Energy Tower, Inc.
(OTCBB: CWET) announced that the Company had filed with the United States Patent & Trademark
Office "A Petition to Make Special Under Accelerated Examination Program," a patent application titled
Efficient Energy Conversion Devices & Methods. The application covers specific aspects of deploying
multiple turbines in a wind tunnel coupled to a novel hydraulic system capable of maintaining high
efficiency hydraulic to electric conversion under a wide variance of wind speeds. The ultimate goal is
to maximize the capture and utilization of all available wind energy in any given wind tunnel, as well as
providing a consistency of power output during deviations in wind speed.
Full news: http://www.investorideas.com/CO/CWE/news/2011/03071.asp
Research more wind stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Wind Company Snapshot
Clean Wind Energy Tower, Inc. (OTCBB: CWET)
Clean Wind Energy, Inc., a wholly owned subsidiary of Clean Wind Energy Tower, Inc., was established
to commercialize a number of proven and validated technologies and construction systems into a single
large downdraft tower structure that use benevolent, non-toxic natural elements to generate electricity
and clean water economically by integrating and synthesizing numerous proven as well as emerging
technologies. In addition to constructing Downdraft Towers in the United States and abroad, Clean Wind
Energy, Inc. has assembled a world class team of experienced business professionals, engineers and
scientists with access to the breakthrough energy research upon which this technology is founded and
the proven ability to bring the idea to market.
Clean Wind has filed several patents that the Company believes will further enhance this potentially
revolutionary technology. The Company intends to establish partnerships at home and abroad to
propagate these systems and meet increasing global demand for clean water and electricity.
www.cleanwindenergytower.com
Visit the showcase page at Investorideas.com: http://www.investorideas.com/CO/CWE/
Broadwind Energy (NASDAQ:BWEN) applies decades of deep industrial expertise to innovate
integrated solutions for customers in the energy and infrastructure markets. From gears to wind towers,
to comprehensive remanufacturing of gearboxes and blades, to operations and maintenance services,
and heavy industries, we have solutions for the energy needs of the future. With facilities throughout
the U.S., Broadwind Energy's talented team of more than 800 employees is committed to helping
customers maximize performance of their investments—quicker, easier and smarter. Find out more at
www.bwen.com.
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy
stocks and has become a global go-to destination for investors researching the cleantech sector, with
stock directories, company news, commentary from experts, research reports and industry resources and
links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on (OTCBB: CWET)
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET)
advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one
thousand five hundred per month, 100,000 144 shares ) to be showcased as a renewable energy stock within its
hub of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer
or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees
as to the accuracy of information presented. All Information relating to featured companies is sourced from public
documents and/ or the company and its management and is not the opinion of Investorideas.com.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com
Company Snapshots for Broadwind Energy, Inc. (NasdaqGS: BWEN ), Clean Wind Energy Tower,
Inc. (OTCBB: CWET)
Point Roberts, WA –March 17, 2011 - Investorideas.com, a leader in cleantech stock research, reports
on recent wind stocks news and developments for wind stocks following a third up day in trading for the
sector. Investors have been turning to renewable stocks this week following the nuclear disaster in Japan.
Astute investors have already been betting on wind. In his most recent shareholder letter, Warren Buffett
stated, “MidAmerican will have 2,909 megawatts of wind generation in operation by the end of 2011,
more than any other regulated electric utility in the country. The total amount that MidAmerican has
invested or committed to wind is a staggering $5.4 billion. We can make this sort of investment because
MidAmerican retains all of its earnings, unlike other utilities that generally pay out most of what they
earn.”
Wind Stocks Snapshot; Morning Trading
Broadwind Energy, Inc. (NasdaqGS: BWEN ) trading at $1.45, up 0.07 (5.07%) 11:02AM EDT
China Ming Yang Wind Power Group (NYSE: MY ) trading at $ 9.39, up 0.09 (0.97%) 11:06AM EDT
Clean Wind Energy Tower, Inc. (OTCBB: CWET) trading at $0.24
Juhl Wind Inc. (OTCBB: JUHL) trading at $1.20, up 0.05 (4.35%)
Plutonic Power Corporation (PCC.TO) trading at $2.55, up 0.06 (2.41%)
Western Wind Energy Corp. (TSX.V: WND) trading at$1.50, up 0.06 (4.17%)
Market Snapshot
Dow 11,743.33 -112.09 -0.95%
Nasdaq 2,649.00 -18.33 -0.69%
S&P 500 1,269.32 -12.55 -0.98%
10 Yr Bond(%) 3.2640% -0.0590
Oil 98.34 +1.16 +1.19%
Gold 1,392.60 0.00 0.00%
Recent Wind News:
Plutonic Power Corporation (TSX: PCC) and Magma Energy Corp. are merging to form Alterra
Power Corp, a renewable power producer
Full news: http://www.investorideas.com/news/2011/renewable-energy/03154.asp
Goldwind Selects Broadwind to Supply Towers for Shady Oaks Project
Experience, flexibility and location made Broadwind the choice for tower localization by China’s
leading wind energy company
Full news: http://finance.yahoo.com/news/Goldwind-Selects-Broadwind-to-bw-29192890.html?x=0&.v=1
Clean Wind Energy Tower, Inc. (OTCBB: CWET) Files Unique Hydraulic System Patent
Maximizing the Capture and Use of Available Wind Tunnel Energy
ANNAPOLIS, MD - March 7, 2011 (InvestorIdeas.com Newswire) - Clean Wind Energy Tower, Inc.
(OTCBB: CWET) announced that the Company had filed with the United States Patent & Trademark
Office "A Petition to Make Special Under Accelerated Examination Program," a patent application titled
Efficient Energy Conversion Devices & Methods. The application covers specific aspects of deploying
multiple turbines in a wind tunnel coupled to a novel hydraulic system capable of maintaining high
efficiency hydraulic to electric conversion under a wide variance of wind speeds. The ultimate goal is
to maximize the capture and utilization of all available wind energy in any given wind tunnel, as well as
providing a consistency of power output during deviations in wind speed.
Full news: http://www.investorideas.com/CO/CWE/news/2011/03071.asp
Research more wind stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Wind Company Snapshot
Clean Wind Energy Tower, Inc. (OTCBB: CWET)
Clean Wind Energy, Inc., a wholly owned subsidiary of Clean Wind Energy Tower, Inc., was established
to commercialize a number of proven and validated technologies and construction systems into a single
large downdraft tower structure that use benevolent, non-toxic natural elements to generate electricity
and clean water economically by integrating and synthesizing numerous proven as well as emerging
technologies. In addition to constructing Downdraft Towers in the United States and abroad, Clean Wind
Energy, Inc. has assembled a world class team of experienced business professionals, engineers and
scientists with access to the breakthrough energy research upon which this technology is founded and
the proven ability to bring the idea to market.
Clean Wind has filed several patents that the Company believes will further enhance this potentially
revolutionary technology. The Company intends to establish partnerships at home and abroad to
propagate these systems and meet increasing global demand for clean water and electricity.
www.cleanwindenergytower.com
Visit the showcase page at Investorideas.com: http://www.investorideas.com/CO/CWE/
Broadwind Energy (NASDAQ:BWEN) applies decades of deep industrial expertise to innovate
integrated solutions for customers in the energy and infrastructure markets. From gears to wind towers,
to comprehensive remanufacturing of gearboxes and blades, to operations and maintenance services,
and heavy industries, we have solutions for the energy needs of the future. With facilities throughout
the U.S., Broadwind Energy's talented team of more than 800 employees is committed to helping
customers maximize performance of their investments—quicker, easier and smarter. Find out more at
www.bwen.com.
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy
stocks and has become a global go-to destination for investors researching the cleantech sector, with
stock directories, company news, commentary from experts, research reports and industry resources and
links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on (OTCBB: CWET)
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET)
advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one
thousand five hundred per month, 100,000 144 shares ) to be showcased as a renewable energy stock within its
hub of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer
or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees
as to the accuracy of information presented. All Information relating to featured companies is sourced from public
documents and/ or the company and its management and is not the opinion of Investorideas.com.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com
Biodefense Stocks; Aethlon Medical (OTCBB:AEMD) Discusses Device Opportunity To Treat Sepsis and Bioterror Threats
San Diego, CA, March 16, 2011 � Investorideas.com newswire; Biotech and biodefense stock news; Aethlon Medical Shareholder Letter Aethlon Medical, Inc., (OTCBB:AEMD) disclosed that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.
Website: aethlonmedical.com
To our Shareholders:
As we advance our Hepatitis-C (HCV) treatment studies in India, we have also been active in our efforts to benefit from new government policies aimed at protecting U.S. civilian and military populations from bioterror and pandemic threats. This policy shift redefines the primary strategic objective of related government agencies to be the identification and support of innovative broad-spectrum countermeasures, technologies, and platforms. This is a considerable shift from the government�s previous focus of attempting to align a single drug or vaccine countermeasure with each pathogen threat. We remain convinced that our Hemopurifier� is the most advanced broad-spectrum countermeasure, technology, or platform.
Earlier this year, we were honored to be invited by The Department of Health and Humans Services (HHS) to present our Hemopurifier� as a broad-spectrum platform technology to multi-agency health officials on January 12th at the Washington Convention Center. Since this presentation, our bioterror and pandemic threat initiative has led to follow-on meetings and presentations, including a formal presentation to the Biomedical Advanced Research and Development Authority (BARDA) on February 15th. While the pursuit of government grants and contracts is not our primary focus, it is difficult to ignore a growing pipeline of new and evolving opportunities to advance our science with non-dilutive capital resources.
On February 8th, we were pleased to learn that the Defense Advanced Research Projects Agency (DARPA) released a broad agency announcement (BAA) entitled: �Dialysis Like Therapeutics� (DLT). The goal of the DLT program is to develop a portable device that removes �dirty� blood from the body, separates harmful agents, and returns �clean� blood to the body in a manner similar to dialysis treatment of kidney failure. While the device could have an impact across multiple areas of medicine, the target application for this device is sepsis. The envisioned device will be capable of removing at least 90% of unknown pathogens, toxins, and activated cells from a patient in one day. As stated in the BAA, targets for removal include viral pathogens referenced to include Hepatitis-C Virus (HCV), Human Immunodeficiency Virus (HIV), Influenza Bio-agents, Smallpox, and viral hemorrhagic fevers. As we have proven capabilities within the scope of this BAA, we plan to respond with a full proposal by April 1st.
If you are not familiar with DARPA, their mission is to maintain the technological superiority of the U.S. military and prevent technological surprise from harming our national security by sponsoring revolutionary, high-payoff research bridging the gap between fundamental discoveries and their military use. Innovation sponsored by DARPA has resulted in groundbreaking discoveries and life changing advances such as the internet. DARPA envisions that the device developed under this BAA would save the lives of thousands of military patients each year.
If selected to participate in the DLT program, we would anticipate a multifaceted role that would involve teaming with other industry partners to advance our core Hemopurifier� as an innovative dialysis-like multi-use platform technology able to selectively target deleterious pathogens and toxins from the entire circulatory system. We would also seek expand the capabilities of our technology platform as the basis for a device targeting to reduce the presence of circulating factors that are precursors to sepsis. Our goal would be to reduce the occurrence of sepsis as post-sepsis treatment strategies to inhibit the inflammation process including the modulation of inflammatory cytokines have yet to be proven clinically beneficial. It is also possible that we could participate in the advancement of portable blood pump technology required under the BAA that would be deployed to treat wounded warfighters with extracorporeal device technologies including current and future iterations of our Hemopurifier� technology. Regardless of outcome, it is truly gratifying to witness therapeutic filtration being the focal point of a government contract opportunity. This is especially true when it comes from an agency as scientifically adept as DARPA. Once we complete our submission to DARPA, I will be back in touch with an update on other activities.
On behalf of our dedicated team at Aethlon Medical, I thank you for your continued support.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier� to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company�s ability to raise capital when needed, including obtaining government grants, the Company�s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the ability to achieve commercialization in India as a result of the proposed treatment program at Medanta, The Medicity Institute, whether successful or not, the ability of the Hemopurifier� to improve the efficacy of SOC therapy against HCV, the Company�s ability to manufacture its products either internally or through outside companies and to create future generations of the Hemopurifier�, the impact of government regulations, patent protection on the Company�s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company�s Securities and Exchange Commission filings.
Disclaimer /Disclosure
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Visit the profile at Investorideas.com: http://www.investorideas.com/co/aemd/
San Diego, CA, March 16, 2011 � Investorideas.com newswire; Biotech and biodefense stock news; Aethlon Medical Shareholder Letter Aethlon Medical, Inc., (OTCBB:AEMD) disclosed that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.
Website: aethlonmedical.com
To our Shareholders:
As we advance our Hepatitis-C (HCV) treatment studies in India, we have also been active in our efforts to benefit from new government policies aimed at protecting U.S. civilian and military populations from bioterror and pandemic threats. This policy shift redefines the primary strategic objective of related government agencies to be the identification and support of innovative broad-spectrum countermeasures, technologies, and platforms. This is a considerable shift from the government�s previous focus of attempting to align a single drug or vaccine countermeasure with each pathogen threat. We remain convinced that our Hemopurifier� is the most advanced broad-spectrum countermeasure, technology, or platform.
Earlier this year, we were honored to be invited by The Department of Health and Humans Services (HHS) to present our Hemopurifier� as a broad-spectrum platform technology to multi-agency health officials on January 12th at the Washington Convention Center. Since this presentation, our bioterror and pandemic threat initiative has led to follow-on meetings and presentations, including a formal presentation to the Biomedical Advanced Research and Development Authority (BARDA) on February 15th. While the pursuit of government grants and contracts is not our primary focus, it is difficult to ignore a growing pipeline of new and evolving opportunities to advance our science with non-dilutive capital resources.
On February 8th, we were pleased to learn that the Defense Advanced Research Projects Agency (DARPA) released a broad agency announcement (BAA) entitled: �Dialysis Like Therapeutics� (DLT). The goal of the DLT program is to develop a portable device that removes �dirty� blood from the body, separates harmful agents, and returns �clean� blood to the body in a manner similar to dialysis treatment of kidney failure. While the device could have an impact across multiple areas of medicine, the target application for this device is sepsis. The envisioned device will be capable of removing at least 90% of unknown pathogens, toxins, and activated cells from a patient in one day. As stated in the BAA, targets for removal include viral pathogens referenced to include Hepatitis-C Virus (HCV), Human Immunodeficiency Virus (HIV), Influenza Bio-agents, Smallpox, and viral hemorrhagic fevers. As we have proven capabilities within the scope of this BAA, we plan to respond with a full proposal by April 1st.
If you are not familiar with DARPA, their mission is to maintain the technological superiority of the U.S. military and prevent technological surprise from harming our national security by sponsoring revolutionary, high-payoff research bridging the gap between fundamental discoveries and their military use. Innovation sponsored by DARPA has resulted in groundbreaking discoveries and life changing advances such as the internet. DARPA envisions that the device developed under this BAA would save the lives of thousands of military patients each year.
If selected to participate in the DLT program, we would anticipate a multifaceted role that would involve teaming with other industry partners to advance our core Hemopurifier� as an innovative dialysis-like multi-use platform technology able to selectively target deleterious pathogens and toxins from the entire circulatory system. We would also seek expand the capabilities of our technology platform as the basis for a device targeting to reduce the presence of circulating factors that are precursors to sepsis. Our goal would be to reduce the occurrence of sepsis as post-sepsis treatment strategies to inhibit the inflammation process including the modulation of inflammatory cytokines have yet to be proven clinically beneficial. It is also possible that we could participate in the advancement of portable blood pump technology required under the BAA that would be deployed to treat wounded warfighters with extracorporeal device technologies including current and future iterations of our Hemopurifier� technology. Regardless of outcome, it is truly gratifying to witness therapeutic filtration being the focal point of a government contract opportunity. This is especially true when it comes from an agency as scientifically adept as DARPA. Once we complete our submission to DARPA, I will be back in touch with an update on other activities.
On behalf of our dedicated team at Aethlon Medical, I thank you for your continued support.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier� to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company�s ability to raise capital when needed, including obtaining government grants, the Company�s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the ability to achieve commercialization in India as a result of the proposed treatment program at Medanta, The Medicity Institute, whether successful or not, the ability of the Hemopurifier� to improve the efficacy of SOC therapy against HCV, the Company�s ability to manufacture its products either internally or through outside companies and to create future generations of the Hemopurifier�, the impact of government regulations, patent protection on the Company�s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company�s Securities and Exchange Commission filings.
Disclaimer /Disclosure
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Visit the profile at Investorideas.com: http://www.investorideas.com/co/aemd/
Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Initiates Hotel and Casino Clean Air Rental Program
CENTERVILLE, MA � March 16, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce it has commenced marketing a clean-air rental program specifically designed for the Hospitality Industry.
The program has been branded as UV Flu "Purity+" Clean Air System, and delivers an aggressively cost effective alternative for hotels and casinos to offer smoke, odor and contaminant-free rooms for their guests. UV Flu Representatives deodorize and monitor contaminants after placing a ViraTech UV-400 in the optimal location within those rooms operating in this innovative new program.
The UV-400 units are designed to kill any bacteria, allergens, and other contaminants, while also reducing any smoke and pet odors with increasing efficacy as room air is passed through the unit multiple times per hour. Company representatives are scheduled at pre-calculated intervals to monitor the room to ensure the UV-400 is performing optimally.
"The UV Flu 'Purity+' Clean Air System offers a significant opportunity for hotel management to increase their REVPAR (revenues per room), improve the level of guest satisfaction, and to decrease the number of room nights lost due to smoke odors in non-smoking rooms," said John Lennon, President of UV Flu. "Our research has shown that in some properties, as many as 1 out of 10 rooms identified as non-smoking exhibited residual smoke odors. The UV-400 can actually process smoke odors as they're being generated, while also killing all other organic contaminants."
Mr. Lennon continues, "Experienced hoteliers know that guests who enjoy fresh-smelling rooms feel healthier and sleep more soundly and report that a pleasurable experience is the key to return visits. Most seasoned travelers are perfectly willing to spend extra for this guaranteed level of service delivery."
"Our ability to provide hotel operators the option to buy, lease, and now rent our UV-400 along with a service program, gives property management the flexibility to find a solution that fits their specific needs. In our first week since we introduced the program we have been asked to provide proposals to properties with a combined room count approaching 20,000 rooms and we believe this momentum is sure to increase in the coming weeks," said Mr. Lennon.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
CENTERVILLE, MA � March 16, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce it has commenced marketing a clean-air rental program specifically designed for the Hospitality Industry.
The program has been branded as UV Flu "Purity+" Clean Air System, and delivers an aggressively cost effective alternative for hotels and casinos to offer smoke, odor and contaminant-free rooms for their guests. UV Flu Representatives deodorize and monitor contaminants after placing a ViraTech UV-400 in the optimal location within those rooms operating in this innovative new program.
The UV-400 units are designed to kill any bacteria, allergens, and other contaminants, while also reducing any smoke and pet odors with increasing efficacy as room air is passed through the unit multiple times per hour. Company representatives are scheduled at pre-calculated intervals to monitor the room to ensure the UV-400 is performing optimally.
"The UV Flu 'Purity+' Clean Air System offers a significant opportunity for hotel management to increase their REVPAR (revenues per room), improve the level of guest satisfaction, and to decrease the number of room nights lost due to smoke odors in non-smoking rooms," said John Lennon, President of UV Flu. "Our research has shown that in some properties, as many as 1 out of 10 rooms identified as non-smoking exhibited residual smoke odors. The UV-400 can actually process smoke odors as they're being generated, while also killing all other organic contaminants."
Mr. Lennon continues, "Experienced hoteliers know that guests who enjoy fresh-smelling rooms feel healthier and sleep more soundly and report that a pleasurable experience is the key to return visits. Most seasoned travelers are perfectly willing to spend extra for this guaranteed level of service delivery."
"Our ability to provide hotel operators the option to buy, lease, and now rent our UV-400 along with a service program, gives property management the flexibility to find a solution that fits their specific needs. In our first week since we introduced the program we have been asked to provide proposals to properties with a combined room count approaching 20,000 rooms and we believe this momentum is sure to increase in the coming weeks," said Mr. Lennon.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp
Tuesday, March 15, 2011
Wind and Solar Stocks Trading News; China Ming Yang Wind (NYSE: MY), Clean Wind Energy
(OTCBB: CWET), Suntech Power (NYSE: STP), Yingli (NYSE: YGE)
Clean Energy Sector Gets a Boost as Concerns on Nuclear Power Mount
Point Roberts, WA –March 16, 2011 - Investorideas.com, a leader in cleantech stock research, reports
on news and trading for solar and wind stocks as investors turn to clean energy in the midst of a potential
nuclear crisis in Japan. The sector began a bullish run in yesterdays trading. In a massive downtrend in
today’s trading, the renewable energy sector is in the green.
From the BP oil spill, to Middle East turmoil spiking oil prices, to the pending nuclear meltdown in Japan;
investors have to ask was cheap energy every really cheap? Clean energy may be the best bet for the
long run- and the short term spike may just be the beginning of a bull run for green investors.
Wind and Solar Stocks Snapshot; Morning Trading
Canadian Solar Inc. (NasdaqGS: CSIQ ) trading at $11.80, up 1.05 (9.77%) 12:34PM EDT
China Ming Yang Wind Power Group (NYSE: MY ) trading at $ 9.33, up 0.13 (1.41%) 12:28PM EDT
China Wind Systems, Inc. (NasdaqGM: CWS ) trading at $ 3.55, up 0.05 (1.43%) 11:26AM EDT
Clean Wind Energy Tower, Inc. (OTCBB: CWET) trading at $0.24 0.00 (0.00%)
First Solar, Inc. (NasdaqGS: FSLR ) trading at $156.23, up $ 9.32 (6.34%) 12:38PM EDT
Juhl Wind Inc. (OTCBB: JUHL) trading at $1.10
Suntech Power (NYSE: STP ) trading at $8.95, up 0.67 (8.09%) 12:35PM EDT
Yingli Green Energy (NYSE: YGE ) trading at $12.0, up 0.76 (6.75%) 12:31PM EDT
Western Wind Energy Corp. (TSX.V: WND) trading at $ 1.43
Market Snapshot
Dow 11,792.60 -200.56 -1.67%
NASDAQ 2,658.08 -42.89 -1.59%
S&P 500 1,276.03 -20.36 -1.57%
10 Yr Bond (%) 3.2970% -0.05
Oil 99.09 -2.10 -2.08%
Gold 1,397.40 -27.20 -1.91%
Investors including Warren Buffet and T. Boone Pickens have bet big on wind energy. With one
environmental disaster after another, the push for clean energy is global.
The European Wind Energy Association (EWEA) reports wind energy alone could meet 28.5% of
Europe´s electricity demand by 2030. Already the Member States´ National Renewable Energy Action
Plans show wind energy providing over 14% of the EU´s electricity by 2020. Full News:
http://www.investorideas.com/news/2011/renewable-energy/03141.asp
In a recent article from the Earth Institute entitled “Wind: The Center of the Plan B Energy Economy”
Earth Policy Institute's Plan B to save civilization has four components: stabilizing climate, restoring
earth's natural support systems, stabilizing population, and eradicating poverty. At the heart of the plan is
a crash program to develop 4,000 gigawatts (4 million megawatts) of wind generating capacity by 2020,
enough to cover over half of world electricity consumption in the Plan B economy. This will require a near
doubling of capacity every two years, up from a doubling every three years over the last decade.
This climate-stabilizing initiative would mean the installation of 2 million wind turbines of 2 megawatts
each. Manufacturing 2 million wind turbines over the next 10 years sounds intimidating—until it is
compared with the 70 million automobiles the world produces each year.
Full article: http://www.investorideas.com/news/2011/renewable-energy/03152.asp
Research more wind stocks and solar stocks with the renewable energy stocks
directory: http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Wind Company Snapshot
Clean Wind Energy Tower, Inc. (OTCBB: CWET)
Clean Wind Energy, Inc., a wholly owned subsidiary of Clean Wind Energy Tower, Inc., was established
to commercialize a number of proven and validated technologies and construction systems into a single
large downdraft tower structure that use benevolent, non-toxic natural elements to generate electricity
and clean water economically by integrating and synthesizing numerous proven as well as emerging
technologies. In addition to constructing Downdraft Towers in the United States and abroad, Clean Wind
Energy, Inc. has assembled a world class team of experienced business professionals, engineers and
scientists with access to the breakthrough energy research upon which this technology is founded and
the proven ability to bring the idea to market.
Clean Wind has filed several patents that the Company believes will further enhance this potentially
revolutionary technology. The Company intends to establish partnerships at home and abroad to
propagate these systems and meet increasing global demand for clean water and electricity.
www.cleanwindenergytower.com
News: Clean Wind Energy Tower, Inc. (OTCBB: CWET) Files Unique Hydraulic
System Patent
Maximizing the Capture and Use of Available Wind Tunnel Energy
ANNAPOLIS, MD - March 7, 2011 (InvestorIdeas.com Newswire) - Clean Wind Energy Tower, Inc.
(OTCBB: CWET) announced that the Company had filed with the United States Patent & Trademark
Office "A Petition to Make Special Under Accelerated Examination Program," a patent application titled
Efficient Energy Conversion Devices & Methods. The application covers specific aspects of deploying
multiple turbines in a wind tunnel coupled to a novel hydraulic system capable of maintaining high
efficiency hydraulic to electric conversion under a wide variance of wind speeds. The ultimate goal is
to maximize the capture and utilization of all available wind energy in any given wind tunnel, as well as
providing a consistency of power output during deviations in wind speed.
Full news: http://www.investorideas.com/CO/CWE/news/2011/03071.asp
Visit the showcase page at Investorideas.com: http://www.investorideas.com/CO/CWE/
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy
stocks and has become a global go-to destination for investors researching the cleantech sector, with
stock directories, company news, commentary from experts, research reports and industry resources and
links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on (OTCBB: CWET)
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET)
advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one
thousand five hundred per month, 100,000 144 shares) to be showcased as a renewable energy stock within its hub
of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer
or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees
as to the accuracy of information presented. All Information relating to featured companies is sourced from public
documents and/ or the company and its management and is not the opinion of Investorideas.com.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com
(OTCBB: CWET), Suntech Power (NYSE: STP), Yingli (NYSE: YGE)
Clean Energy Sector Gets a Boost as Concerns on Nuclear Power Mount
Point Roberts, WA –March 16, 2011 - Investorideas.com, a leader in cleantech stock research, reports
on news and trading for solar and wind stocks as investors turn to clean energy in the midst of a potential
nuclear crisis in Japan. The sector began a bullish run in yesterdays trading. In a massive downtrend in
today’s trading, the renewable energy sector is in the green.
From the BP oil spill, to Middle East turmoil spiking oil prices, to the pending nuclear meltdown in Japan;
investors have to ask was cheap energy every really cheap? Clean energy may be the best bet for the
long run- and the short term spike may just be the beginning of a bull run for green investors.
Wind and Solar Stocks Snapshot; Morning Trading
Canadian Solar Inc. (NasdaqGS: CSIQ ) trading at $11.80, up 1.05 (9.77%) 12:34PM EDT
China Ming Yang Wind Power Group (NYSE: MY ) trading at $ 9.33, up 0.13 (1.41%) 12:28PM EDT
China Wind Systems, Inc. (NasdaqGM: CWS ) trading at $ 3.55, up 0.05 (1.43%) 11:26AM EDT
Clean Wind Energy Tower, Inc. (OTCBB: CWET) trading at $0.24 0.00 (0.00%)
First Solar, Inc. (NasdaqGS: FSLR ) trading at $156.23, up $ 9.32 (6.34%) 12:38PM EDT
Juhl Wind Inc. (OTCBB: JUHL) trading at $1.10
Suntech Power (NYSE: STP ) trading at $8.95, up 0.67 (8.09%) 12:35PM EDT
Yingli Green Energy (NYSE: YGE ) trading at $12.0, up 0.76 (6.75%) 12:31PM EDT
Western Wind Energy Corp. (TSX.V: WND) trading at $ 1.43
Market Snapshot
Dow 11,792.60 -200.56 -1.67%
NASDAQ 2,658.08 -42.89 -1.59%
S&P 500 1,276.03 -20.36 -1.57%
10 Yr Bond (%) 3.2970% -0.05
Oil 99.09 -2.10 -2.08%
Gold 1,397.40 -27.20 -1.91%
Investors including Warren Buffet and T. Boone Pickens have bet big on wind energy. With one
environmental disaster after another, the push for clean energy is global.
The European Wind Energy Association (EWEA) reports wind energy alone could meet 28.5% of
Europe´s electricity demand by 2030. Already the Member States´ National Renewable Energy Action
Plans show wind energy providing over 14% of the EU´s electricity by 2020. Full News:
http://www.investorideas.com/news/2011/renewable-energy/03141.asp
In a recent article from the Earth Institute entitled “Wind: The Center of the Plan B Energy Economy”
Earth Policy Institute's Plan B to save civilization has four components: stabilizing climate, restoring
earth's natural support systems, stabilizing population, and eradicating poverty. At the heart of the plan is
a crash program to develop 4,000 gigawatts (4 million megawatts) of wind generating capacity by 2020,
enough to cover over half of world electricity consumption in the Plan B economy. This will require a near
doubling of capacity every two years, up from a doubling every three years over the last decade.
This climate-stabilizing initiative would mean the installation of 2 million wind turbines of 2 megawatts
each. Manufacturing 2 million wind turbines over the next 10 years sounds intimidating—until it is
compared with the 70 million automobiles the world produces each year.
Full article: http://www.investorideas.com/news/2011/renewable-energy/03152.asp
Research more wind stocks and solar stocks with the renewable energy stocks
directory: http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Wind Company Snapshot
Clean Wind Energy Tower, Inc. (OTCBB: CWET)
Clean Wind Energy, Inc., a wholly owned subsidiary of Clean Wind Energy Tower, Inc., was established
to commercialize a number of proven and validated technologies and construction systems into a single
large downdraft tower structure that use benevolent, non-toxic natural elements to generate electricity
and clean water economically by integrating and synthesizing numerous proven as well as emerging
technologies. In addition to constructing Downdraft Towers in the United States and abroad, Clean Wind
Energy, Inc. has assembled a world class team of experienced business professionals, engineers and
scientists with access to the breakthrough energy research upon which this technology is founded and
the proven ability to bring the idea to market.
Clean Wind has filed several patents that the Company believes will further enhance this potentially
revolutionary technology. The Company intends to establish partnerships at home and abroad to
propagate these systems and meet increasing global demand for clean water and electricity.
www.cleanwindenergytower.com
News: Clean Wind Energy Tower, Inc. (OTCBB: CWET) Files Unique Hydraulic
System Patent
Maximizing the Capture and Use of Available Wind Tunnel Energy
ANNAPOLIS, MD - March 7, 2011 (InvestorIdeas.com Newswire) - Clean Wind Energy Tower, Inc.
(OTCBB: CWET) announced that the Company had filed with the United States Patent & Trademark
Office "A Petition to Make Special Under Accelerated Examination Program," a patent application titled
Efficient Energy Conversion Devices & Methods. The application covers specific aspects of deploying
multiple turbines in a wind tunnel coupled to a novel hydraulic system capable of maintaining high
efficiency hydraulic to electric conversion under a wide variance of wind speeds. The ultimate goal is
to maximize the capture and utilization of all available wind energy in any given wind tunnel, as well as
providing a consistency of power output during deviations in wind speed.
Full news: http://www.investorideas.com/CO/CWE/news/2011/03071.asp
Visit the showcase page at Investorideas.com: http://www.investorideas.com/CO/CWE/
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy
stocks and has become a global go-to destination for investors researching the cleantech sector, with
stock directories, company news, commentary from experts, research reports and industry resources and
links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on (OTCBB: CWET)
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET)
advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one
thousand five hundred per month, 100,000 144 shares) to be showcased as a renewable energy stock within its hub
of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer
or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees
as to the accuracy of information presented. All Information relating to featured companies is sourced from public
documents and/ or the company and its management and is not the opinion of Investorideas.com.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com
Cleantech Stock Trading News; Electric Car Pioneer, Richard H. Griffiths, Joins EVCARCO, Inc. (OTCBB: EVCA) as Chief Communications Officer
FT. WORTH, TX - March 15, 2011 (Investorideas.com renewable energy/green newswire) - EVCARCO, Inc. (OTCBB:EVCA) (Pinksheets:EVCA) announced today that well known electric vehicle marketing expert, Richard H Griffiths, has accepted the position of Chief Communications Officer. Mr. Griffiths, http://en.wikipedia.org/wiki/Richard_H._Griffiths, is an electric vehicle marketing expert as well as a Senior Government Advisor for the U.S. State Department, Government of Colombia, Republic of Tanzania and the Kingdom of Thailand. He will develop strategic relationships with governments, Hollywood celebrities and persons of influence in North America and globally. Mr. Griffiths has been successful in getting electric vehicles on media shows such as Regis and Kelly, FOX, CNN and was featured on the History Channel as one of the early pioneers of electric vehicles.
Mack Sanders, CEO of EVCARCO, stated, "Richard's work in getting New York City to place electric powered taxi cabs throughout the City, as well as his placement of electric smart cars for sale through Sam's Club, has earned him a reputation in the alternate fuel industry. Having Richard head up the Ambassador of Sustainability� program will enable us to have a dialogue with Hollywood stars and will give our brand the attention required to get consumer and investor interest."
Mr. Griffiths stated, "It is an honor to be associated with EVCARCO. The team assembled at EVCA has a high level of experience in this field and will be focused on bringing the very best alternative energy vehicles to market."
For more information on EVCARCO, Inc., please view: www.evcarco.com. Shareholder inquiries should be directed to (972) 571-1624.
EVCARCO Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
This Press Release contains certain forward-looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
FT. WORTH, TX - March 15, 2011 (Investorideas.com renewable energy/green newswire) - EVCARCO, Inc. (OTCBB:EVCA) (Pinksheets:EVCA) announced today that well known electric vehicle marketing expert, Richard H Griffiths, has accepted the position of Chief Communications Officer. Mr. Griffiths, http://en.wikipedia.org/wiki/Richard_H._Griffiths, is an electric vehicle marketing expert as well as a Senior Government Advisor for the U.S. State Department, Government of Colombia, Republic of Tanzania and the Kingdom of Thailand. He will develop strategic relationships with governments, Hollywood celebrities and persons of influence in North America and globally. Mr. Griffiths has been successful in getting electric vehicles on media shows such as Regis and Kelly, FOX, CNN and was featured on the History Channel as one of the early pioneers of electric vehicles.
Mack Sanders, CEO of EVCARCO, stated, "Richard's work in getting New York City to place electric powered taxi cabs throughout the City, as well as his placement of electric smart cars for sale through Sam's Club, has earned him a reputation in the alternate fuel industry. Having Richard head up the Ambassador of Sustainability� program will enable us to have a dialogue with Hollywood stars and will give our brand the attention required to get consumer and investor interest."
Mr. Griffiths stated, "It is an honor to be associated with EVCARCO. The team assembled at EVCA has a high level of experience in this field and will be focused on bringing the very best alternative energy vehicles to market."
For more information on EVCARCO, Inc., please view: www.evcarco.com. Shareholder inquiries should be directed to (972) 571-1624.
EVCARCO Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
This Press Release contains certain forward-looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Subscribe to:
Posts (Atom)